靶向长新冠中的SARS-CoV-2储存库
长新冠(COVID-19后状况)尚无获批治疗,估计影响数千万人。越来越多证据显示部分个体感染后SARS-CoV-2可持续数月或数年,该储存库可能驱动长新冠症状或后遗症,因此亟需靶向持续病毒的临床试验。本文提出此类试验在设计、实施与解读方面的关键考量,借鉴HIV储存库、丙型肝炎、其他RNA病毒及精准肿瘤学试验的经验。
要点
- 长新冠尚无获批治疗,部分个体SARS-CoV-2可持续数月或数年,储存库可能驱动症状或后遗症。
- 多项针对长新冠的抗病毒药或单克隆抗体试验正在进行,但病毒持续机制尚未完全阐明。
- 试验设计需考虑候选治疗作用机制、受试者选择、疗程、储存库相关生物标志物标准化及结局评估。
核心结论
- 长新冠尚无获批治疗,需开展靶向持续SARS-CoV-2的临床试验,并重视试验设计、实施与解读的关键考量。
研究设计与样本
- 本文为综述与观点类文章,基于HIV储存库、丙型肝炎、其他RNA病毒及精准肿瘤学试验的经验提出建议。
主要发现
- 越来越多证据显示部分个体COVID-19后SARS-CoV-2可持续数月或数年,该储存库可能驱动长新冠症状或后遗症。
- 多项针对长新冠的抗病毒药或单克隆抗体试验正在进行。
- SARS-CoV-2持续机制尚未完全阐明,相关研究需考虑候选治疗作用机制、受试者选择、疗程、储存库相关生物标志物标准化与可测量指标、最佳结局评估及潜在联合方案。
- 患者亚组可能对某些干预或联合干预有应答,事后分析至关重要。
临床怎么用
- 作者建议长新冠试验设计需考虑候选治疗作用机制、受试者选择、疗程、储存库相关生物标志物标准化与可测量指标、最佳结局评估及潜在联合方案。
- 作者认为患者亚组可能对某些干预或联合干预有应答,事后分析至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are no approved treatments for post-COVID-19 condition (also known as long COVID), a debilitating disease state following SARS-CoV-2 infection that is estimated to affect tens of millions of people. A growing body of evidence shows that SARS-CoV-2 can persist for months or years following COVID-19 in a subset of individuals, with this reservoir potentially driving long-COVID symptoms or sequelae. There is, therefore, an urgent need for clinical trials targeting persistent SARS-CoV-2, and several trials of antivirals or monoclonal antibodies for long COVID are underway. However, because mechanisms of SARS-CoV-2 persistence are not yet fully understood, such studies require important considerations related to the mechanism of action of candidate therapeutics, participant selection, duration of treatment, standardisation of reservoir-associated biomarkers and measurables, optimal outcome assessments, and potential combination approaches. In addition, patient subgroups might respond to some interventions or combinations of interventions, making post-hoc analyses crucial. Here, we outline these and other key considerations, with the goal of informing the design, implementation, and interpretation of trials in this rapidly growing field. Our recommendations are informed by knowledge gained from trials targeting the HIV reservoir, hepatitis C, and other RNA viruses, as well as precision oncology, which share many of the same hurdles facing long-COVID trials.
引用
- Proal AD, Aleman S, Bomsel M, et al. Targeting the SARS-CoV-2 reservoir in long COVID. Lancet Infect Dis. 2025. PMID: 39947217. doi:10.1016/S1473-3099(24)00769-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。